Market Segmentation:
- By Product Type
- Prescription sleep medications
- Over-the-counter sleep aids
- Medical devices (e.g., CPAP machines)
- Others (herbal supplements, melatonin)
- By Insomnia Type
- Chronic insomnia
- Acute insomnia
- Comorbid insomnia
- Others (paradoxical insomnia, idiopathic insomnia)
- By Distribution Channel
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
- Others (clinics, sleep centers)
- By Treatment
- Pharmacological treatments
- Non-pharmacological treatments (e.g., CBT, relaxation techniques)
- Others (light therapy, acupuncture)
- By End User
- Hospitals
- Sleep centers
- Clinics
- Home care settings
- Others (nursing homes, assisted living facilities)
- By Cause
- Medical conditions (e.g., chronic pain, cancer)
- Psychiatric disorders (e.g., anxiety, depression)
- Substance abuse
- Lifestyle factors (e.g., stress, jet lag)
- Hormonal imbalances
- Others (medications, environmental factors)
- By Age Group
- Pediatric insomnia
- Adult insomnia
- Geriatric insomnia
- By Regions
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Frequently Asked Questions
The current market size of the Global Insomnia industry is USD 3.2 billion.
The key factors driving the growth of the Global Insomnia Market include increasing prevalence of insomnia, rising stress and anxiety levels, growing aging population, unhealthy lifestyle factors, development of novel insomnia drugs, adoption of digital therapeutics, increasing awareness and diagnosis, and expanding usage of wearable devices.
The key factors hampering the growth of the Global Insomnia Market include side effects of insomnia medications, high cost of treatment, lack of awareness in underdeveloped regions, and stringent regulatory guidelines.
The leading component segment in the Global Insomnia Market is the prescription sleep medications segment, which is used to treat insomnia effectively.
The major players operating in the Global Insomnia Market include Sanofi, Merck & Co., Pfizer Inc., Takeda Pharmaceutical Company Limited, Eisai Co., Ltd., Idorsia Pharmaceuticals Ltd., Minerva Neurosciences, Inc., Sumitomo Dainippon Pharma Co., Ltd., Mylan N.V., and Teva Pharmaceutical Industries Ltd.
The North America region is expected to lead the Global Insomnia Market, with a market share of 35.8% in 2023. The Global Insomnia Market is expected to grow at a CAGR of 11.2% from 2023 to 2031, reaching a market size of USD 7.5 billion by 2031.
The key drivers of the Global Insomnia Market include increasing prevalence of insomnia, rising stress and anxiety levels, growing aging population, development of novel insomnia drugs, and increasing awareness and diagnosis.